Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Aeglea Biotherapeutics (AGLE) and Neurosense Therapeutics Ltd. (NRSN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aeglea Biotherapeutics (AGLEResearch Report) and Neurosense Therapeutics Ltd. (NRSNResearch Report).

Aeglea Biotherapeutics (AGLE)

Aeglea Biotherapeutics received a Hold rating from Needham analyst Gil Blum today. The company’s shares closed last Thursday at $0.74.

According to TipRanks.com, Blum has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -36.5% and a 16.2% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Aeglea Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.83, which is a 533.7% upside from current levels. In a report released today, Piper Sandler also downgraded the stock to Hold with a $1.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Neurosense Therapeutics Ltd. (NRSN)

Maxim Group analyst Naz Rahman maintained a Buy rating on Neurosense Therapeutics Ltd. yesterday and set a price target of $7.00. The company’s shares closed last Thursday at $1.42, close to its 52-week low of $1.23.

According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -41.8% and a 11.1% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Processa Pharmaceuticals, Galmed Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Neurosense Therapeutics Ltd. is a Moderate Buy with an average price target of $7.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AGLE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed